JPMorgan analyst Christopher Schott noted that Coherus Biosciences pre-announced Q2 Udenyca sales that were well above consensus expectations in the mid-$40M range, though modestly below his prior estimate of $91M. The preannouncement also suggested slightly higher discounting relative to Symphony sales trends than in Q1, but he does not see this as "particularly concerning," said Schott. The analyst, who called the selloff in shares not warranted following the pre-announcement, maintains an Overweight rating on Coherus shares, which are down $3.39, or 15%, to $19.35 in late morning trading.